AstraZeneca PLC (AZN)
NASDAQ: AZN · Real-Time Price · USD
72.12
-0.32 (-0.44%)
May 5, 2025, 12:34 PM EDT - Market open
AstraZeneca Revenue
AstraZeneca had revenue of $13.59B in the quarter ending March 31, 2025, with 7.17% growth. This brings the company's revenue in the last twelve months to $54.98B, up 15.48% year-over-year. In the year 2024, AstraZeneca had annual revenue of $54.07B with 18.03% growth.
Revenue (ttm)
$54.98B
Revenue Growth
+15.48%
P/S Ratio
4.03
Revenue / Employee
$583,054
Employees
94,300
Market Cap
221.69B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 54.07B | 8.26B | 18.03% |
Dec 31, 2023 | 45.81B | 1.46B | 3.29% |
Dec 31, 2022 | 44.35B | 6.93B | 18.53% |
Dec 31, 2021 | 37.42B | 10.80B | 40.58% |
Dec 31, 2020 | 26.62B | 2.23B | 9.16% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
Novartis AG | 53.22B |
Eli Lilly and Company | 49.00B |
Thermo Fisher Scientific | 42.90B |
Abbott Laboratories | 42.34B |
AZN News
- 3 days ago - AstraZeneca's Breztri meets main goals of late-stage asthma trials - Reuters
- 6 days ago - AstraZeneca PLC (AZN) Q1 2025 Earnings Conference Call Transcript - Seeking Alpha
- 6 days ago - AstraZeneca Q1 Earnings Rise, But China Drug Allegations May Lead To $8 Million Penalty - Benzinga
- 6 days ago - AstraZeneca to keep 2025 forecast if US pharmaceutical tariffs in line with other sectors - Reuters
- 6 days ago - AstraZeneca Sales, Earnings Rise; Warns of Mounting Legal Challenges in China - WSJ
- 6 days ago - AstraZeneca says may face further import tax fine from China - Reuters
- 6 days ago - AstraZeneca's Q1 2025 Financial Results - Business Wire
- 7 days ago - SOPHiA GENETICS Announces Expanded Collaboration with AstraZeneca to Accelerate Liquid Biopsy Testing Globally from AACR - PRNewsWire